How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Round led by PXN Ventures, with additional funding from existing investors IQ Capital and Northern Gritstone * Company uses quantum physics, AI m ...

Like most vendor event keynotes this year, Michael Dell used his Dell Technologies World 2026 keynote to argue that ...

The company's closed-loop platform is designed to dramatically speed up enzyme development for pharmaceuticals, sustainable ...

A Manchester-based techbio company using AI and quantum physics to engineer better enzymes faster, has closed a £5 million ...

Gaming has become a vital research area in the most advanced forms of decision algorithms, optimization, and procedural ...

Gemini Omni is Google’s attempt to make AI video creation feel less like operating a stack of separate tools and more like directing a scene through conversation. Announced by Google as a model that ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Discover what AI model collapse is, its causes, early warning signs, and severe consequences. Learn how to prevent recursive ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.